½ÃÀ庸°í¼­
»óǰÄÚµå
1349969

¼¼Æ÷ ¹× À¯ÀüÀÚ Ä¡·á ½ÃÀå : Ä¡·á À¯Çüº°, ¿ëµµº°, ÃÖÁ¾ »ç¿ëÀÚº°, Áö¿ªº°: ±Ô¸ð, Á¡À¯À², Àü¸Á, ±âȸ ºÐ¼®(2023-2030³â)

Cell and Gene Therapy Market, By Therapy Type, By Application, By End User, By Geography (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa)- Size, Share, Outlook, and Opportunity Analysis, 2023 - 2030

¹ßÇàÀÏ: | ¸®¼­Ä¡»ç: Coherent Market Insights | ÆäÀÌÁö Á¤º¸: ¿µ¹® | ¹è¼Û¾È³» : 2-3ÀÏ (¿µ¾÷ÀÏ ±âÁØ)

    
    
    




¡Ø º» »óǰÀº ¿µ¹® ÀÚ·á·Î Çѱ۰ú ¿µ¹® ¸ñÂ÷¿¡ ºÒÀÏÄ¡ÇÏ´Â ³»¿ëÀÌ ÀÖÀ» °æ¿ì ¿µ¹®À» ¿ì¼±ÇÕ´Ï´Ù. Á¤È®ÇÑ °ËÅ並 À§ÇØ ¿µ¹® ¸ñÂ÷¸¦ Âü°íÇØÁֽñ⠹ٶø´Ï´Ù.

¼¼°è ¼¼Æ÷ ¹× À¯ÀüÀÚ Ä¡·á ½ÃÀåÀº 2023³â 227¾ï ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹»óµÇ¸ç, ¿¹Ãø ±â°£(2023-2030³â) µ¿¾È 28.7%ÀÇ CAGRÀ» ³ªÅ¸³¾ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù.

º¸°í¼­ ¹üÀ§ º¸°í¼­ »ó¼¼
±âÁس⵵ 2022 2023³â ½ÃÀå ±Ô¸ð 227¾ï ´Þ·¯
°ú°Å µ¥ÀÌÅÍ 2018³âºÎÅÍ 2021³â±îÁö ¿¹Ãø ±â°£ 2023-2030
¿¹Ãø ±â°£(2023-2030³â)ÀÇ CAGR: 28.70% 2030³â °¡Ä¡ ¿¹Ãø 1,326¾ï ´Þ·¯
¼¼Æ÷ ¹× À¯ÀüÀÚ Ä¡·áÁ¦ ½ÃÀå-IMG1

¼¼Æ÷Ä¡·á´Â ȯÀÚÀÇ ½Åü¿¡ »õ·Î¿î ¼¼Æ÷¸¦ µµÀÔÇÏ¿© Áúº´ Ä¡·á¸¦ À§ÇØ ¼Õ»óµÈ Á¶Á÷À» Áõ½Ä, ´ëü, º¹±¸ÇÏ´Â °ÍÀ» ¸»ÇÕ´Ï´Ù. ¼¼Æ÷Ä¡·á¿¡´Â Áٱ⼼Æ÷, ¸²ÇÁ±¸, ¼öÁö»ó¼¼Æ÷ µî ´Ù¾çÇÑ À¯ÇüÀÇ ¼¼Æ÷¸¦ »ç¿ëÇÒ ¼ö ÀÖ½À´Ï´Ù. ¼¼Æ÷Ä¡·á¿¡´Â ȯÀÚ ÀÚ½ÅÀÇ ¸ö¿¡¼­ äÃëÇÑ ¼¼Æ÷(ÀÚ°¡¼¼Æ÷)¿Í ±âÁõÀڷκÎÅÍ Ã¤ÃëÇÑ ¼¼Æ÷(µ¿Á¾¼¼Æ÷)°¡ »ç¿ëµË´Ï´Ù. ¸¹Àº ¼¼Æ÷Ä¡·á´Â À¯ÀüÀûÀ¸·Î ÀçÇÁ·Î±×·¡¹ÖµÇ¾î ȯÀÚÀÇ ¸ö¿¡¼­ ¿©·¯ À¯ÇüÀÇ ¼¼Æ÷ Áß Çϳª°¡ µÉ ¼ö ÀÖ´Â ¼ºÃ¼ ¼¼Æ÷¸¦ »ç¿ëÇÕ´Ï´Ù. ÀÌ ±â¼úÀ» ÅëÇØ Ä¡·á ¸ñÀû¿¡ ÇÊ¿äÇÑ Æ¯Á¤ Àΰ£ ¼¼Æ÷¸¦ ¹«Á¦ÇÑÀ¸·Î °³¹ßÇÒ ¼ö ÀÖ´Â °¡´É¼ºÀÌ ÀÖ½À´Ï´Ù.

À¯ÀüÀÚ Ä¡·á´Â Áúº´ÀÇ Ä¡·á, ¿¹¹æ ¶Ç´Â Ä¡·á °¡´É¼ºÀ» ¸ñÀûÀ¸·Î ȯÀÚÀÇ ½Åü¿¡ À¯ÀüÀÚ¸¦ º¯ÇüÇϰųª µµÀÔÇÏ´Â °ÍÀÔ´Ï´Ù. À¯ÀüÀÚ Ä¡·áÀÇ Á¢±Ù¹ýÀÇ ¿¹·Î´Â Áúº´À» À¯¹ßÇÏ´Â µ¹¿¬º¯ÀÌµÈ À¯ÀüÀÚ¸¦ ±â´ÉÀûÀÎ »çº»À¸·Î ´ëüÇϰųª »õ·Î¿î ¿Ã¹Ù¸¥ À¯ÀüÀÚ »çº»À» ü³»¿¡ µµÀÔÇÏ´Â °ÍÀ» µé ¼ö ÀÖ½À´Ï´Ù.

½ÃÀå ¿ªÇÐ

¼¼Æ÷ ¹× À¯ÀüÀÚ Ä¡·á´Â À¯ÀüÀÚ Á¶Àý, ¼¼Æ÷ °£ »óÈ£ ÀÛ¿ë, Àç»ý ´É·Â ¹× ¸®¸ðµ¨¸µ¿¡ »ç¿ëÇÒ ¼ö ÀÖ´Â °³³ä°ú ±â¼úÀ» Á¦°øÇϱ⠶§¹®¿¡ Çö´ë ÀÇ·á¿¡¼­ Áß¿äÇÑ ¿ªÇÒÀ» Çϰí ÀÖ½À´Ï´Ù. µû¶ó¼­ ÁÖ¿ä ½ÃÀå Âü¿©ÀÚµéÀº Á¦Ç°/Ç÷§Æû Ãâ½Ã¿Í °°Àº ´Ù¾çÇÑ ¼ºÀå Àü·«À» µµÀÔÇÏ´Â µ¥ ÁÖ·ÂÇϰí ÀÖÀ¸¸ç, ±× °á°ú ¿¹Ãø ±â°£ µ¿¾È ½ÃÀå ¼ºÀåÀ» °¡¼ÓÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ¿¹¸¦ µé¾î, 2023³â 4¿ù 4ÀÏ ¼¼°è ÇコÄÉ¾î ±â¾÷ AmerisourceBergenÀº ¼¼Æ÷ ¹× À¯ÀüÀÚ Ä¡·á(CGT) ÅëÇÕ ÇãºêÀÇ Ãâ½Ã¸¦ ¹ßÇ¥Çß½À´Ï´Ù. ÀÌ ½Ã½ºÅÛÀº ¹ÙÀÌ¿À Á¦¾à ¹× °ø±ÞÀÚ¸¦ À§ÇÑ Ç÷§Æû°ú ÅëÇÕÇÒ ¼ö ÀÖÀ¸¸ç, ½Ç½Ã°£ µ¥ÀÌÅÍ ±³È¯À» ¿ëÀÌÇÏ°Ô Çϰí, Ä¡·á °³¹ß ¹× ÆäÀ̼¾Æ®ÀÇ ¿©Á¤ Àü¹Ý¿¡ °ÉÃÄ ¼­ºñ½º¸¦ ±¸¼ºÇÒ ¼ö ÀÖµµ·Ï Áö¿øÇÕ´Ï´Ù.

º» Á¶»çÀÇ ÁÖ¿ä Æ¯Â¡

  • ÀÌ º¸°í¼­´Â 2022³âÀ» ±âÁØ¿¬µµ·Î ÇÏ¿© ¿¹Ãø ±â°£(2023-2030³â) ½ÃÀå ±Ô¸ð¿Í ¿¬Æò±Õ ¼ºÀå·ü(CAGR)À» Á¦½ÃÇÏ´Â ¼¼°è ¼¼Æ÷ ¹× À¯ÀüÀÚ Ä¡·á ½ÃÀåÀ» »ó¼¼ÇÏ°Ô ºÐ¼®ÇÏ¿´½À´Ï´Ù.
  • ¶ÇÇÑ ´Ù¾çÇÑ ºÎ¹®ÀÇ ÀáÀçÀû ¼öÀÍ ±âȸ¸¦ ÆÄ¾ÇÇϰí, ÀÌ ½ÃÀå¿¡ ´ëÇÑ ¸Å·ÂÀûÀÎ ÅõÀÚ Á¦¾È ¸ÅÆ®¸¯½º¸¦ ¼³¸íÇÕ´Ï´Ù.
  • ¶ÇÇÑ ½ÃÀå ¼ºÀå ÃËÁø¿äÀÎ, ¾ïÁ¦¿äÀÎ, ±âȸ, ½ÅÁ¦Ç° Ãâ½Ã ¹× ½ÂÀÎ, ½ÃÀå µ¿Çâ, Áö¿ªº° Àü¸Á, ÁÖ¿ä ±â¾÷ÀÌ Ã¤ÅÃÇÑ °æÀï Àü·« µî¿¡ ´ëÇÑ Áß¿äÇÑ °í·Á »çÇ×µµ Á¦°øÇÕ´Ï´Ù.
  • ¼¼°è ¼¼Æ÷ ¹× À¯ÀüÀÚ Ä¡·áÁ¦ ½ÃÀåÀÇ ÁÖ¿ä ±â¾÷À» ±â¾÷ ÇÏÀ̶óÀÌÆ®, Á¦Ç° Æ÷Æ®Æú¸®¿À, ÁÖ¿ä ÇÏÀ̶óÀÌÆ®, À繫 ¼º°ú, Àü·« µîÀÇ ¸Å°³ º¯¼ö¸¦ ±â¹ÝÀ¸·Î ÇÁ·ÎÆÄÀϸµÇÕ´Ï´Ù.
  • º» Á¶»ç ´ë»óÀÇ ÁÖ¿ä ±â¾÷À¸·Î´Â Novartis International AG, Pfizer, Inc. Celgene Corporation), Biogen Inc. Limited, Gilead Sciences, Inc. Therapeutics, Inc., Spark Therapeutics, Inc. µîÀÌ ÀÖ½À´Ï´Ù.
  • ÀÌ º¸°í¼­ÀÇ ÅëÂû·ÂÀ» ÅëÇØ ¸¶ÄÉÆÃ ´ã´çÀÚ¿Í ±â¾÷ °æ¿µÁøÀº ÇâÈÄ Á¦Ç° Ãâ½Ã, À¯ÇüÈ­, ½ÃÀå È®´ë ¹× ¸¶ÄÉÆÃ Àü¼ú¿¡ ´ëÇÑ Á¤º¸¿¡ ÀÔ°¢ÇÑ ÀÇ»ç°áÁ¤À» ³»¸± ¼ö ÀÖ½À´Ï´Ù.
  • ¼¼°è ¼¼Æ÷ ¹× À¯ÀüÀÚ Ä¡·á ½ÃÀå º¸°í¼­´Â ÅõÀÚÀÚ, °ø±Þ¾÷ü, Á¦Ç° Á¦Á¶¾÷ü, À¯Åë¾÷ü, ½Å±Ô ½ÃÀå ÁøÃâ±â¾÷, À繫 ºÐ¼®°¡ µî ÀÌ »ê¾÷ÀÇ ´Ù¾çÇÑ ÀÌÇØ°ü°èÀÚ¸¦ ´ë»óÀ¸·Î ÇÕ´Ï´Ù.
  • ÀÌÇØ°ü°èÀÚ´Â ¼¼°è ¼¼Æ÷ ¹× À¯ÀüÀÚ Ä¡·á ½ÃÀå ºÐ¼®¿¡ »ç¿ëµÇ´Â ´Ù¾çÇÑ Àü·« ¸ÅÆ®¸¯½º¸¦ ÅëÇØ ÀÇ»ç°áÁ¤À» ¿ëÀÌÇÏ°Ô ÇÒ ¼ö ÀÖ½À´Ï´Ù.

¸ñÂ÷

Á¦1Àå Á¶»ç ¸ñÀû°ú ÀüÁ¦Á¶°Ç

  • Á¶»ç ¸ñÀû
  • ÀüÁ¦Á¶°Ç
  • ¾à¾î

Á¦2Àå ½ÃÀå »óȲ °³¿ä

  • º¸°í¼­ °³¿ä
    • ½ÃÀå Á¤ÀÇ¿Í ¹üÀ§
  • ÁÖ¿ä ¿ä¾à
  • Coherent Opportunity Map(COM)

Á¦3Àå ½ÃÀå ¿ªÇÐ, ±ÔÁ¦, µ¿Ç⠺м®

  • ½ÃÀå ¿ªÇÐ
    • ¼ºÀå ÃËÁø¿äÀÎ
    • ¼ºÀå ¾ïÁ¦¿äÀÎ
    • ½ÃÀå ±âȸ
  • ¿µÇ⠺м®
  • ÇÕº´, Àμö, Á¦ÈÞ
  • ±ÔÁ¦ ½Ã³ª¸®¿À
  • ÁÖ¿ä ¹ßÀü
  • PEST ºÐ¼®
  • ±â¼úÀû Áøº¸
  • Á¦Á¶¾÷ü ¸ÅÃâ
  • ÆÄÀÌÇÁ¶óÀÎ ºÐ¼®

Á¦4Àå ¼¼°èÀÇ ¼¼Æ÷ ¹× À¯ÀüÀÚ Ä¡·á ½ÃÀå - COVID-19ÀÇ ¿µÇ⠺м®

  • °æÁ¦Àû ¿µÇâ
  • COVID-19 ¿ªÇÐ
  • ¼ö±Þ¿¡ ´ëÇÑ ¿µÇâ

Á¦5Àå ¼¼°èÀÇ ¼¼Æ÷ ¹× À¯ÀüÀÚ Ä¡·á ½ÃÀå : Ä¡·á À¯Çüº°, 2018³â-2030³â

  • ¼¼Æ÷Ä¡·á
  • Áٱ⼼Æ÷
  • T¼¼Æ÷
  • ¼ö»ó¼¼Æ÷
  • NK¼¼Æ÷
  • À¯ÀüÀÚ Ä¡·á
  • »ý½Ä ¼¼Æ÷ À¯ÀüÀÚ Ä¡·á
  • ü¼¼Æ÷ À¯ÀüÀÚ Ä¡·á

Á¦6Àå ¼¼°èÀÇ ¼¼Æ÷ ¹× À¯ÀüÀÚ Ä¡·á ½ÃÀå : ¿ëµµº°, 2018³â-2030³â

  • ÇǺΰúÇÐ
  • ±Ù°ñ°Ý°è
  • Á¾¾çÇÐ
  • ¸é¿ªÇÐ
  • ½ÉÀ庴ÇС¤½Å°æÇÐ
  • ±âŸ(ºñ´¢±â Áúȯ, °¨¿°Áõ, ¾È°ú Áúȯ, ¸Á¸· Áúȯ, ±âŸ)

Á¦7Àå ¼¼°èÀÇ ¼¼Æ÷ ¹× À¯ÀüÀÚ Ä¡·á ½ÃÀå : ÃÖÁ¾»ç¿ëÀÚº°, 2018³â-2030³â

  • º´¿ø
  • Áø·á¼Ò
  • ±âŸ(¿¬±¸±â°ü, Çмú±â°ü µî)

Á¦8Àå ¼¼°èÀÇ ¼¼Æ÷ ¹× À¯ÀüÀÚ Ä¡·á ½ÃÀå : Áö¿ªº°, 2018³â-2030³â

  • ºÏ¹Ì
  • ¹Ì±¹
  • ij³ª´Ù
  • ¶óƾ¾Æ¸Þ¸®Ä«
  • ºê¶óÁú
  • ¸ß½ÃÄÚ
  • ¾Æ¸£ÇîÆ¼³ª
  • ±âŸ ¶óƾ¾Æ¸Þ¸®Ä«
  • À¯·´
  • ¿µ±¹
  • µ¶ÀÏ
  • ÀÌÅ»¸®¾Æ
  • ÇÁ¶û½º
  • ½ºÆäÀÎ
  • ·¯½Ã¾Æ
  • ±âŸ À¯·´
  • ¾Æ½Ã¾ÆÅÂÆò¾ç
  • Áß±¹
  • Àεµ
  • ÀϺ»
  • ASEAN
  • È£ÁÖ
  • Çѱ¹
  • ±âŸ ¾Æ½Ã¾ÆÅÂÆò¾ç
  • Áßµ¿
  • GCC
  • À̽º¶ó¿¤
  • ±âŸ Áßµ¿
  • ¾ÆÇÁ¸®Ä«
  • ºÏ¾ÆÇÁ¸®Ä«
  • Áß¾Ó¾ÆÇÁ¸®Ä«
  • ³²¾ÆÇÁ¸®Ä«

Á¦9Àå °æÀï ±¸µµ

  • Novartis International AG
  • Pfizer, Inc.
  • Sanofi S.A.
  • Amgen, Inc.
  • Regeneron Pharmaceuticals, Inc.
  • Bluebird Bio, Inc.(Celgene Corporation)
  • Biogen Inc.
  • uniQure N.V.
  • JCR Pharmaceuticals Co. Ltd.
  • Gene Biotherapeutics
  • Kolon TissueGene, Inc.
  • Horama S.A.
  • MeiraGTx Limited
  • Gilead Sciences, Inc.
  • Organogenesis, Inc.
  • Orchard Therapeutics Plc.
  • Freeline Therapeutics Ltd.
  • Bristol-Myers Squibb Company
  • PTC Therapeutics, Inc.
  • Spark Therapeutics, Inc.
  • Biomarin Pharmaceutical Inc.

Á¦10Àå ¼½¼Ç

  • Á¶»ç ¹æ¹ý
  • ÃâÆÇ»ç¿¡ ´ëÇØ
LSH 23.10.06

The global cell and gene therapy market is estimated to be valued at US$ 22.7 billion in 2023 and is expected to exhibit a CAGR of 28.7% during the forecast period (2023-2030).

Report Coverage Report Details
Base Year: 2022 Market Size in 2023: US$ 22.7 Bn
Historical Data for: 2018 to 2021 Forecast Period: 2023 - 2030
Forecast Period 2023 to 2030 CAGR: 28.70% 2030 Value Projection: US$ 132.6 Bn
Cell and Gene Therapy Market - IMG1

Cell therapy is the introduction of new cells into a patient's body to grow, replace, or repair damaged tissue in order to treat a disease. A variety of different types of cells can be used in cell therapy, including stem cells, lymphocytes, and dendritic cells. Cell therapies can use cells from the patient's own body (autologous) or from a donor (allogenic). Many cell therapies use adult cells that have been genetically reprogrammed and capable of becoming one of many types of cells inside a patient's body. This technology may enable the development of unlimited types of specific human cells needed for therapeutic purposes.

Gene therapy seeks to modify or introduce genes into a patient's body with the goal of treating, preventing, or potentially curing a disease. Examples of gene therapy approaches include replacing a mutated gene that causes disease with a functional copy or introducing a new, correct copy of a gene into the body.

Market Dynamics

Cell and gene therapy plays a major role in modern healthcare, as it provides concepts and techniques that can be used in gene regulation, cell-cell interactions, regenerative capacity, and remodeling. Thus, key market players are focused on adopting various growth strategies such as product/platform launches and others, which in turn is expected to fuel the market growth over the forecast period. For instance, on April 4, 2023, AmerisourceBergen, a global healthcare company, announced the launch of its Cell and Gene Therapy (CGT) Integration Hub, a system that can be integrated with biopharma or provider-facing platforms to facilitate real-time data exchange and help orchestrate services across the treatment development and patient journey.

Furthermore, The CGT Integration Hub, which is platform-agnostic and powered by AmerisourceBergen's innovative customer relationship management (CRM) system, aims to streamline the path-to-care process, in part, by providing physicians and patient services teams with enhanced visibility across the therapy development and delivery process. Through platform integrations, the CGT Integration Hub can:

  • Speed up the benefits investigation process so that after physicians enter patient enrollment data, they can get a decision on the patient's coverage almost immediately.
  • To facilitate patient scheduling, give doctors and care managers real-time access to information on the status of the development of the therapy and transportation.
  • Inform case managers of any status changes, such as postponed arrival dates, so they can contact patients and caregivers in advance to amend any scheduled treatment-related activities or stays, as necessary.

Key features of the study:

  • This report provides an in-depth analysis of the global cell and gene therapy market and provides market size (US$ Billion) and compound annual growth rate (CAGR) for the forecast period (2023-2030), considering 2022 as the base year
  • It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
  • This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
  • It profiles key players in the global cell and gene therapy market based on the following parameters-Company highlights, products portfolio, key highlights, financial performance, and strategies
  • Key companies covered as a part of this study include Novartis International AG, Pfizer, Inc., Sanofi S.A., Amgen, Inc., Regeneron Pharmaceuticals, Inc., Bluebird Bio, Inc. (Celgene Corporation) , Biogen Inc., uniQure N.V., JCR Pharmaceuticals Co. Ltd., Gene Biotherapeutics, Kolon TissueGene, Inc., Horama S.A., MeiraGTx Limited, Gilead Sciences, Inc., Organogenesis, Inc., Orchard Therapeutics Plc., Freeline Therapeutics Ltd. , Bristol-Myers Squibb Company, PTC Therapeutics, Inc., Spark Therapeutics, Inc. and Biomarin Pharmaceutical Inc.
  • Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
  • Global cell and gene therapy market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
  • Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global cell and gene therapy market

Detailed Segmentation:

  • Global Cell and Gene Therapy Market, By Therapy Type:
    • Cell Therapy
    • Stem Cells
    • T Cells
    • Dendritic Cells
    • NK Cells
    • Gene Therapy
    • Germline Gene Therapy
    • Somatic Gene Therapy
  • Global Cell and Gene Therapy Market, By Application:
    • Dermatology
    • Musculoskeletal
    • Oncology
    • Immunology
    • Cardiology & Neurology
    • Others (Urinary Problems, Infectious Disease, Ophthalmic, Diseases, Retinal Diseases, And Others)
  • Global Cell and Gene Therapy Market, By End user:
    • Hospitals
    • Clinics
    • Others (Research Institutes, Academic Institutes, etc.)
  • Global Cell and Gene Therapy Market, By Region:
    • North America
    • U.S.
    • Canada
    • Latin America
    • Brazil
    • Mexico
    • Argentina
    • Rest of Latin America
    • Europe
    • Germany
    • U.K.
    • France
    • Italy
    • Spain
    • Russia
    • Rest of Europe
    • Asia Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
    • ASEAN
    • Rest of Asia Pacific
    • Middle East
    • GCC
    • Israel
    • Rest of Middle East
    • Africa
    • South Africa
    • Central Africa
    • North Africa
  • Company Profiles
    • Novartis International AG
    • Pfizer, Inc.
    • Sanofi S.A.
    • Amgen, Inc.
    • Regeneron Pharmaceuticals, Inc.
    • Bluebird Bio, Inc. (Celgene Corporation)
    • Biogen Inc.
    • uniQure N.V.
    • JCR Pharmaceuticals Co. Ltd.
    • Gene Biotherapeutics
    • Kolon TissueGene, Inc.
    • Horama S.A.
    • MeiraGTx Limited
    • Gilead Sciences, Inc.
    • Organogenesis, Inc.
    • Orchard Therapeutics Plc.
    • Freeline Therapeutics Ltd.
    • Bristol-Myers Squibb Company
    • PTC Therapeutics, Inc.
    • Spark Therapeutics, Inc.
    • Biomarin Pharmaceutical Inc.

Table of Contents

1. Research Objectives and Assumptions

  • Research Objectives
  • Assumptions
  • Abbreviations

2. Market Purview

  • Report Description
    • Market Definition and Scope
  • Executive Summary
    • Market Snapshot, By Therapy Type
    • Market Snapshot, By Application
    • Market Snapshot, By End user
    • Market Snapshot, By Region
  • Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

  • Market Dynamics
    • Drivers
    • Restraints
    • Market Opportunities
  • Impact Analysis
  • Merger, Acquisition, and Collaborations
  • Regulatory Scenario
  • Key Developments
  • PEST Analysis
  • Technological Advancements
  • Manufacturer Revenue
  • Pipeline Analysis

4. Global Cell and Gene Therapy Market - COVID-19 Impact Analysis

  • Economic Impact
  • COVID-19 Epidemiology
  • Impact on Supply and Demand

5. Global Cell and Gene Therapy Market, By Therapy Type, 2018 - 2030, (US$ Billion)

  • Introduction
    • Market Share Analysis, 2023 and 2030 (%)
    • Y-o-Y Growth Analysis, 2018-2030
    • Segment Trends
  • Cell Therapy
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018 - 2030, (US$ Billion)
    • Segment Trends
  • Stem Cells
  • T Cells
  • Dendritic Cells
  • NK Cells
  • Gene Therapy
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018 - 2030, (US$ Billion)
    • Segment Trends
  • Germline Gene Therapy
  • Somatic Gene Therapy

6. Global Cell and Gene Therapy Market, By Application, 2018 - 2030, (US$ Billion)

  • Introduction
    • Market Share Analysis, 2023 and 2030 (%)
    • Y-o-Y Growth Analysis, 2018-2030
    • Segment Trends
  • Dermatology
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018 - 2030, (US$ Billion)
    • Segment Trends
  • Musculoskeletal
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018 - 2030, (US$ Billion)
    • Segment Trends
  • Oncology
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018 - 2030, (US$ Billion)
    • Segment Trends
  • Immunology
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018 - 2030, (US$ Billion)
    • Segment Trends
  • Cardiology & Neurology
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018 - 2030, (US$ Billion)
    • Segment Trends
  • Others (Urinary Problems, Infectious Disease, Ophthalmic, Diseases, Retinal Diseases, And Others)
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018 - 2030, (US$ Billion)
    • Segment Trends

7. Global Cell and Gene Therapy Market, By End user, 2018 - 2030, (US$ Billion)

  • Introduction
    • Market Share Analysis, 2023 and 2030 (%)
    • Y-o-Y Growth Analysis, 2018-2030
    • Segment Trends
  • Hospitals
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018 - 2030, (US$ Billion)
  • Clinics
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018 - 2030, (US$ Billion)
  • Others (Research Institutes, Academic Institutes, etc.)
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018 - 2030, (US$ Billion)

8. Global Cell and Gene Therapy Market, By Region, 2018 - 2030, (US$ Billion)

  • Introduction
    • Market Share Analysis, By Region, 2023 and 2030 (%)
    • Y-o-Y Growth Analysis, For Regions, 2018-2030
    • Regional Trends
  • North America
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, By Therapy Type, 2018 - 2030, (US$ Billion)
    • Market Size and Forecast, and Y-o-Y Growth, By Application, 2018 - 2030, (US$ Billion)
    • Market Size and Forecast, and Y-o-Y Growth, By End user, 2018 - 2030, (US$ Billion)
    • Market Size and Forecast, and Y-o-Y Growth, By Country , 2018 - 2030, (US$ Billion)
  • U.S.
  • Canada
  • Latin America
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, By Therapy Type, 2018 - 2030, (US$ Billion)
    • Market Size and Forecast, and Y-o-Y Growth, By Application, 2018 - 2030, (US$ Billion)
    • Market Size and Forecast, and Y-o-Y Growth, By End user, 2018 - 2030, (US$ Billion)
    • Market Size and Forecast, and Y-o-Y Growth, By Country , 2018 - 2030, (US$ Billion)
  • Brazil
  • Mexico
  • Argentina
  • Rest of Latin America
  • Europe
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, By Therapy Type, 2018 - 2030, (US$ Billion)
    • Market Size and Forecast, and Y-o-Y Growth, By Application, 2018 - 2030, (US$ Billion)
    • Market Size and Forecast, and Y-o-Y Growth, By End user, 2018 - 2030, (US$ Billion)
    • Market Size and Forecast, and Y-o-Y Growth, By Country , 2018 - 2030, (US$ Billion)
  • U.K.
  • Germany
  • Italy
  • France
  • Spain
  • Russia
  • Rest of Europe
  • Asia Pacific
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, By Therapy Type, 2018 - 2030, (US$ Billion)
    • Market Size and Forecast, and Y-o-Y Growth, By Application, 2018 - 2030, (US$ Billion)
    • Market Size and Forecast, and Y-o-Y Growth, By End user, 2018 - 2030, (US$ Billion)
    • Market Size and Forecast, and Y-o-Y Growth, By Country , 2018 - 2030, (US$ Billion)
  • China
  • India
  • Japan
  • ASEAN
  • Australia
  • South Korea
  • Rest of Asia Pacific
  • Middle East
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, By Therapy Type, 2018 - 2030, (US$ Billion)
    • Market Size and Forecast, and Y-o-Y Growth, By Application, 2018 - 2030, (US$ Billion)
    • Market Size and Forecast, and Y-o-Y Growth, By End user, 2018 - 2030, (US$ Billion)
    • Market Size and Forecast, and Y-o-Y Growth, By Country , 2018 - 2030, (US$ Billion)
  • GCC
  • Israel
  • Rest of Middle East
  • Africa
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, By Therapy Type, 2018 - 2030, (US$ Billion)
    • Market Size and Forecast, and Y-o-Y Growth, By Application, 2018 - 2030, (US$ Billion)
    • Market Size and Forecast, and Y-o-Y Growth, By End user, 2018 - 2030, (US$ Billion)
    • Market Size and Forecast, and Y-o-Y Growth, By Country , 2018 - 2030, (US$ Billion)
  • North Africa
  • Central Africa
  • South Africa

9. Competitive Landscape

  • Novartis International AG*
    • Company Highlights
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Market Strategies
  • Pfizer, Inc.
  • Sanofi S.A.
  • Amgen, Inc.
  • Regeneron Pharmaceuticals, Inc.
  • Bluebird Bio, Inc. (Celgene Corporation)
  • Biogen Inc.
  • uniQure N.V.
  • JCR Pharmaceuticals Co. Ltd.
  • Gene Biotherapeutics
  • Kolon TissueGene, Inc.
  • Horama S.A.
  • MeiraGTx Limited
  • Gilead Sciences, Inc.
  • Organogenesis, Inc.
  • Orchard Therapeutics Plc.
  • Freeline Therapeutics Ltd.
  • Bristol-Myers Squibb Company
  • PTC Therapeutics, Inc.
  • Spark Therapeutics, Inc.
  • Biomarin Pharmaceutical Inc.

10. Section

  • Research Methodology
  • About Us
»ùÇà ¿äû ¸ñ·Ï
0 °ÇÀÇ »óǰÀ» ¼±Åà Áß
¸ñ·Ï º¸±â
Àüü»èÁ¦